# | Date | Product | Risk | Measures |
1 | 5/2016 |
|
Administration and mentoring.
|
|
2 | 5/2016 |
|
- Growth.
- Risk of Contamination Risk of Contamination .
|
|
3 | 5/2016 |
|
- Nephropathies including anti-GBM disease.
- Thyroid DisordersThyroid Disorders.
- Serious InfectionsSerious Infections
|
|
4 | 3/2016 |
|
- Endophthalmitis.
- Cataract.
- Intraocular pressure increased
- Overdose due to overfill of the prefilled syringe.Overdose due to overfill of the prefilled syringe.
|
|
5 | 3/2016 |
|
- Serious infections including opportunistic infections and TB.
- Hepatitis B virus reactivation.
- Congestive heart failure. Congestive heart failure.
- Serious systemic hypersensitivity.
- Skin cancer.
- Administration error.
|
|
6 | 3/2016 |
Methylphenidate (Ritalin®)
|
- Growth.
- Psychiatric and cardiovascular status monitoring.
|
|
7 | 3/2016 |
|
Interference with blood compatibility testing .
|
|
8 | 3/2016 |
|
- Hepatotoxicity.
- Thrombotic/thromboembolic complications.Thrombotic/thromboembolic complications.
- Bone marrow reticulin formation Risk for bone marrow fibrosis Haematological malignancies.
- Post therapy thrombocytopenia Interactions with foods.Post therapy thrombocytopenia Interactions with foods.
|
|
9 | 3/2016 |
Mycophenolate mofetil (Cellcept®)
|
- Teratogenicity.Teratogenicity.
- spontaneous abortions.
- congenital malformations following exposure during pregnancy.
|
|
10 | 2/2016 |
Zoledronic acid (Zometa®)
|
Osteonecrosis of the jaw (ONJ).
|
|